{"nctId":"NCT01235507","briefTitle":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)","startDateStruct":{"date":"2011-02"},"conditions":["Rheumatoid Arthritis"],"count":71,"armGroups":[{"label":"Single Arm","type":"EXPERIMENTAL","interventionNames":["Drug: methotrexate","Drug: tocilizumab [RoActemra/Actemra]"]}],"interventions":[{"name":"methotrexate","otherNames":[]},{"name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients, \\>/= 18 years of age\n* Active moderate to severe rheumatoid arthritis (RA)\n* On methotrexate treatment (oral or parenteral) for at least 12 weeks, at stable dose of at least 15 mg/week for at least 6 weeks\n* Oral corticosteroids must have been at stable dose of \\</= 10 mg/day prednisone (or equivalent) for at least 25 out of 28 days prior to first dose of study drug\n* Body weight \\</= 150 kg\n\nExclusion Criteria:\n\n* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months of study entry\n* Rheumatic autoimmune disease other than RA\n* Functional class IV according to American College of Rheumatology (ACR) classification\n* Prior history of or current inflammatory joint disease other then RA\n* Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline\n* Treatment with any biologic drug that is used in the treatment or RA\n* Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline\n* Known active current or history of recurrent infection\n* History of or currently active primary or secondary immunodeficiency\n* Positive for HIV","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Mean Disease Activity Score Based on 28 Joint Count (DAS28) by Visit","description":"DAS28 was calculated using the 28 joints count, the C-reactive protein levels (CRP) and participant's global assessment (PtGA) of disease activity. The following formula was used to determine DAS28.\n\nDAS28 (equals) = 0.56 × (square root of) √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100- millimeter \\[mm\\] visual analog scale \\[ VAS\\]).\n\nThe DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.28","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.84","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.44","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.19","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.09","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.62","spread":"1.22"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Low Disease Activity (LDA) and Clinical Remission (CR) as Assessed Using DAS28","description":"DAS28 was calculated using the 28 joints count, the CRP and PtGA of disease activity. The following formula was used to determine DAS28.\n\nDAS28 = 0.56 × √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100-mm VAS).\n\nThe DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Participants were considered to have low disease activity when DAS28 was less than or equal to (≤) 3.2 and in clinical remission when DAS28 scores were less than (\\<) 2.6","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Swollen and Tender Joint Counts","description":"66 and 68 joints were assessed by the physician for tenderness or swelling respectively. The joints were counted as tender/not tender (tender=1; not tender=0) and swollen/not swollen (swollen=1; not swollen=0) and scored. The scores ranged from 0 to 66 for TJC and 0 to 68 for SJC. A negative change from baseline represents an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.48","spread":"10.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.72","spread":"5.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.76","spread":"10.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.73","spread":"4.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.75","spread":"9.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.43","spread":"4.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.83","spread":"9.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.62","spread":"11.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.59","spread":"8.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.03","spread":"12.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.12","spread":"7.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.49","spread":"11.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.03","spread":"5.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.48","spread":"10.27"}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment of Disease Activity","description":"Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.44","spread":"17.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.99","spread":"20.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.45","spread":"17.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.48","spread":"20.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.97","spread":"20.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.28","spread":"17.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.09","spread":"19.69"}]}]}]},{"type":"SECONDARY","title":"Participant's Global Assessment of Disease Activity","description":"Participant's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":"16.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.87","spread":"20.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.13","spread":"21.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.20","spread":"21.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.80","spread":"22.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.56","spread":"20.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.30","spread":"22.74"}]}]}]},{"type":"SECONDARY","title":"Participant's Global Assessment of Pain","description":"Participant's global assessment of pain was performed using a 100 mm VAS ranging from no pain (0) at the left edge to unbearable pain (100) at the right edge. The distance in mm from the left edge of the scale was measured. A negative change from baseline represents an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.73","spread":"17.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.34","spread":"19.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.39","spread":"19.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.94","spread":"21.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.79","spread":"21.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.54","spread":"21.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.04","spread":"25.11"}]}]}]},{"type":"SECONDARY","title":"CRP Levels","description":"CRP is a marker of acute phase inflammation and is measured in mg/L. A negative change from baseline represents an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.98","spread":"15.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.11","spread":"14.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.68","spread":"17.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.84","spread":"11.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","spread":"18.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.53","spread":"14.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.97","spread":"21.12"}]}]}]},{"type":"SECONDARY","title":"Erythrocyte Sedimentation Rate (ESR)","description":"ESR is a marker of inflammation and is measured in millimeters per hour (mm/hour). A negative change from baseline represents an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.13","spread":"24.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.04","spread":"8.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.09","spread":"22.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.71","spread":"6.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.42","spread":"23.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"12.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.72","spread":"27.54"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)","description":"AEs, SAEs and AESI were recorded from the Screening Visit until the final visit at Week 24.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":71},"commonTop":["Leukocytopenia","Elevated AST","Thrombocytopenia"]}}}